Compare PRCT & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCT | ADNT |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.7B |
| IPO Year | 2021 | 2016 |
| Metric | PRCT | ADNT |
|---|---|---|
| Price | $25.22 | $21.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $35.44 | $25.59 |
| AVG Volume (30 Days) | ★ 1.1M | 768.7K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $308,054,000.00 | ★ $17,439,000,000.00 |
| Revenue This Year | $31.34 | $2.71 |
| Revenue Next Year | $24.52 | $2.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 37.22 | 7.56 |
| 52 Week Low | $19.35 | $11.09 |
| 52 Week High | $64.89 | $27.32 |
| Indicator | PRCT | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 50.21 | 57.21 |
| Support Level | $22.81 | $18.69 |
| Resistance Level | $28.57 | $21.76 |
| Average True Range (ATR) | 1.24 | 0.88 |
| MACD | 0.18 | 0.20 |
| Stochastic Oscillator | 65.64 | 70.74 |
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.